Dr. Lili Yang received her Ph.D. degree in Biology from the California Institute of Technology (Caltech) in 2004, trained at the Laboratory of David Baltimore. She led the Engineering Immunity Program at Caltech from 2004 to 2012, developing immunotherapies for cancer and HIV/AIDS. She joined the University of California, Los Angeles (UCLA) as an Assistant Professor in 2013. Her laboratory at UCLA studies tumor immunology and cancer immunotherapy, with a special focus on stem cell-based and gene-engineered immunotherapy for cancer. Her work resulted in 29 publications, 10 patents, and 2 clinical trials.
For the recognition of her scientific achievements, Dr. Lili Yang has received multiple prestigious awards, notably a TR35 (Innovators Under 35) Award from the MIT Technology Review Magazine, a Director’s New Innovator Award from the National Institute of Health (NIH), and an Outstanding New Investigator Award from the American Society of Gene & Cell Therapy (ASGCT).